Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK), AbbVie Inc (ABBV): Will This HIV Triumph Change History?

Page 1 of 2

Last year will long be remembered for its remarkable advances in the diagnosis and prevention of HIV; OraSure Technologies gained FDA approval for the first-ever at-home, over-the-counter, and needle-free HIV test, while Gilead Sciences, Inc. (NASDAQ: GILD)‘s drug Truvada, a therapeutic initially prescribed only for HIV-positive patients, was approved as a prophylactic medication for at-risk individuals.

But now, just months into 2013, a landmark discovery in the treatment — rather than prevention — of HIV has been announced.

Pfizer Inc. (NYSE:PFE)Public health phenomenon
Late Sunday evening, a number of media outlets reported that a child who had been infected with HIV at birth in 2010 had been cured following a course of treatment that lasted only a year and a half. According to the physicians involved in the infant’s care, a mixture of three drugs — commonly referred to as a “cocktail” — was administered to the infant just 30 hours after birth.

There have been varying reports as to the exact combination that was used, but an article published by Bloomberg stated that two drugs made by a Pfizer Inc. (NYSE:PFE) and GlaxoSmithKline plc (ADR) (NYSE:GSK) joint venture — lamivudine and zidovudine — along with AbbVie Inc (NYSE:ABBV)‘s Kaletra formed the treatment.The newborn was kept on the drugs for only 18 months and, for reasons that are still unclear, was not treated for the next 10 months. Miraculously, after relocating the child, doctors could not find any evidence that the patient was still infected with the disease.

The limited data available today suggests that it was the swift intervention of the doctors involved in this infant’s care that made the difference; administering this drug cocktail as soon after birth as possible, rather than days or weeks afterwards, could be the key to curing HIV-positive newborns.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!